TransMedics Group (NASDAQ:TMDX) Stock Falls 5.7% – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price traded down 5.7% during trading on Friday. The stock traded as low as $71.01 and last traded at $72.1670. 197,648 shares changed hands during trading, a decline of 80% from the average session volume of 1,000,373 shares. The stock had previously closed at $76.52.

Analysts Set New Price Targets

Several brokerages have weighed in on TMDX. Piper Sandler restated an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. TD Cowen restated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research note on Tuesday, September 8th. Barclays began coverage on TransMedics Group in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective for the company. Finally, Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $95.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday. Five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, TransMedics Group has a consensus rating of “Hold” and an average price target of $115.60.

TransMedics Group Stock Down 6.0%

The business’s 50 day moving average price is $85.81 and its 200-day moving average price is $82.99. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The firm has a market capitalization of $2.49 billion, a PE ratio of 18.47, a P/E/G ratio of 1.04 and a beta of 1.94.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter last year, the business earned $0.92 earnings per share. The business’s revenue was up 20.7% compared to the same quarter last year. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Insider Buying and Selling

In other news, Director David Weill acquired 1,336 shares of the company’s stock in a transaction on Friday, September 11th. The shares were bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the acquisition, the director owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.90% of the stock is owned by corporate insiders.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Silvant Capital Management LLC acquired a new position in TransMedics Group in the 2nd quarter valued at about $26,000. North Star Investment Management Corp. purchased a new position in shares of TransMedics Group during the 1st quarter worth approximately $30,000. Ascentis Independent Advisors acquired a new stake in shares of TransMedics Group in the 1st quarter valued at approximately $30,000. State of Wyoming purchased a new position in TransMedics Group in the second quarter worth $31,000. Finally, Ancora Advisors LLC acquired a new stake in TransMedics Group in the second quarter valued at $33,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.